Results
Patients randomised to the treatment arm experienced the following benefits:
- reduced relapse rates:
- non-significant at 1 year
- 18% reduction at 2 years
- reduced disease burden as assessed by T2-weighted MRI scans
- a significant delay in six-month confirmed progression of one point on the EDSS:
- the clinical significance of this difference has been doubted
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.